PDCD1 and cancer: It has emerged that blockade of CTLA-4/CD80/CD86, the “brakes” of the immune system, and the blockade of the PD-1/PD-L1 axis, which suppresses T-lymphocyte proliferation, survival, and effector functions, can potentially reactivate “depleted” T cells in infectious diseases and cancer.